Search results
Geron Shares Surge After U.S. FDA Approves Blood Disorder Drug
US News & World Report· 1 day agoThe injectable drug will compete with Bristol Myers Squibb's Reblozyl, which received a label expansion green light by the regulator last year for the same ...
2 No-Brainer Dividend Stocks You Can Buy With $100 in June
Motley Fool via Yahoo Finance· 5 days agoThe company's growth portfolio raised first-quarter sales by 11% year over year if we exclude the...
Bristol Myers Squibb’s Breyanzi shows promise in B-cell malignancy clinical trials
Clinical Trials Arena via Yahoo Finance· 4 days agoBreyanzi has obtained accelerated approval from the US Food and Drug Administration for adults with...
Geron shares surge after U.S. FDA approves blood disorder drug
WSAU Wausau· 1 day ago(Reuters) - Shares of Geron rose almost 16% on Friday before market, a day after getting its first...
Bristol’s $250,000 pill slows lung cancer growth by 7 weeks
San Francisco Chronicle· 5 days agoA Bristol Myers Squibb Co. lung cancer treatment delayed tumor growth by less than seven weeks in a closely watched clinical trial, a disappointing result after the company ...
I-Mab and BMS assess givastomig for gastric and oesophageal cancer
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe US Food and Drug Administration (FDA) awarded orphan drug designation to givastomig to treat ...
2 No-Brainer Dividend Stocks You Can Buy With $100 in June | The Motley Fool
The Motley Fool· 5 days agoInvestors looking for stocks that can deliver satisfying returns with limited risk want to turn...
Geron Corp stock opened 25% up on Friday: here's why | Invezz
Invezz· 22 hours agoAre you looking for signals & alerts from pro-traders? The Food & Drug Administration approved its lead asset as a late-line treatment ...
ASCO 2024: Precede Biosciences assay classifies HER2 and ER status in cancers
Clinical Trials Arena via Yahoo Finance· 5 days agoAstraZeneca’s ADC Enhertu (trastuzumab deruxtecan) recently received US Food and Drug Administration...
GSK builds case for return of multiple myeloma drug Blenrep
BioPharma Dive via Yahoo Finance· 6 days agoStudy results showed the antibody-drug conjugate helped stave off disease progression better than a...